Full press release for #epclusa here. FDA PDUFA date is June 28 #HCV http://www.businesswire.com/news/financialpost/20160527005292/en/European-CHMP-Adopts-Positive-Opinion-Gilead%E2%80%99s-Epclusa%C2%AE
European CHMP Adopts Positive Opinion for Gilead’s Epclus...
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that ...
www.businesswire.com
December 3, 2024 at 9:27 AM
Full press release for #epclusa here. FDA PDUFA date is June 28 #HCV http://www.businesswire.com/news/financialpost/20160527005292/en/European-CHMP-Adopts-Positive-Opinion-Gilead%E2%80%99s-Epclusa%C2%AE
Ever wonder how drugs like #ocaliva #zepatier or #epclusa get their name? http://www.boston.com/lifestyle/health/blog/inpractice/2012/07/how_are_drugs_named.html
Page not found | Boston.com
www.boston.com
December 3, 2024 at 9:27 AM
Ever wonder how drugs like #ocaliva #zepatier or #epclusa get their name? http://www.boston.com/lifestyle/health/blog/inpractice/2012/07/how_are_drugs_named.html
FDA approves Epclusa for treatment of chronic #HCV infection http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm508915.htm
FDA approves Epclusa for treatment of chronic Hepatitis C...
The U.S. Food and Drug Administration approved Epclusa to...
www.fda.gov
December 3, 2024 at 9:17 AM
FDA approves Epclusa for treatment of chronic #HCV infection http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm508915.htm
Medications soon no longer protected by patents or Gilead will offer Epclusa, a three-month regimen of pills that cures hepatitis C, for $2,492 a month on the site. Gilead says “typically a person taking Epclusa pays between $0 and $5 per month” with commercial insurance or Medicare. So no deals.
“Medicare for All is how we take our power back and build a system that puts people over profits,” said Rep. Pramila Jayapal.
As Trump Touts 9 New Prescription Drug Deals, Many Call for Systemic Reform
The ongoing battle over Affordable Care Act subsidies has renewed calls for Medicare for All.
buff.ly
December 20, 2025 at 4:23 PM
Medications soon no longer protected by patents or Gilead will offer Epclusa, a three-month regimen of pills that cures hepatitis C, for $2,492 a month on the site. Gilead says “typically a person taking Epclusa pays between $0 and $5 per month” with commercial insurance or Medicare. So no deals.
Gilead (Gilead.com) charges $24,920 for one month of the HCV medication Epclusa, but manufacturing its ingredients (11.2g Sofosbuvir and 2.8g Velpatasvir, my calculations) costs only about $27.66 total. Based on production costs, Americans are being overcharged by approximately 90,000%.
Happy? 😠
Happy? 😠
December 22, 2025 at 11:37 PM
Gilead (Gilead.com) charges $24,920 for one month of the HCV medication Epclusa, but manufacturing its ingredients (11.2g Sofosbuvir and 2.8g Velpatasvir, my calculations) costs only about $27.66 total. Based on production costs, Americans are being overcharged by approximately 90,000%.
Happy? 😠
Happy? 😠
If that was true then how did Epclusa or Mavyret make it to the market?
July 11, 2026 at 9:03 PM
If that was true then how did Epclusa or Mavyret make it to the market?
About ten years ago, I had a friend that had to take an anti viral called Epclusa, for HEP-C.
88 days , one pill per day.
The cost of the three month regimen was right at $75,000.
Now, it will be $93,750 for 88 pills.
A little more.
It's made in India, where the entire three months cost $600.
88 days , one pill per day.
The cost of the three month regimen was right at $75,000.
Now, it will be $93,750 for 88 pills.
A little more.
It's made in India, where the entire three months cost $600.
August 4, 2025 at 10:04 AM
About ten years ago, I had a friend that had to take an anti viral called Epclusa, for HEP-C.
88 days , one pill per day.
The cost of the three month regimen was right at $75,000.
Now, it will be $93,750 for 88 pills.
A little more.
It's made in India, where the entire three months cost $600.
88 days , one pill per day.
The cost of the three month regimen was right at $75,000.
Now, it will be $93,750 for 88 pills.
A little more.
It's made in India, where the entire three months cost $600.
There’s some medicine called EPCLUSA, which sounds like an acronym for an Episcopal-Presbyterian-Lutheran combined denomination. ⚓️
December 1, 2023 at 7:10 AM
There’s some medicine called EPCLUSA, which sounds like an acronym for an Episcopal-Presbyterian-Lutheran combined denomination. ⚓️
Sofosbuvir/Velpatasvir (SOF/VEL)Epclusa:
-requires baseline RAS testing for genotype 3
-12 weeks of tx: 1 tablet daily
-suitable for patients with decompensated cirrhosis.
-requires baseline RAS testing for genotype 3
-12 weeks of tx: 1 tablet daily
-suitable for patients with decompensated cirrhosis.
November 28, 2024 at 4:06 AM
Sofosbuvir/Velpatasvir (SOF/VEL)Epclusa:
-requires baseline RAS testing for genotype 3
-12 weeks of tx: 1 tablet daily
-suitable for patients with decompensated cirrhosis.
-requires baseline RAS testing for genotype 3
-12 weeks of tx: 1 tablet daily
-suitable for patients with decompensated cirrhosis.
“Atea ran the pivotal C-Beyond study to compare its once-daily fixed-dose combination of bemnifosbuvir & ruzasvir (BEM/RZR) to Gilead’s incumbent hepatitis C drug..a once-daily fixed-dose combination of sofosbuvir & velpatasvir, as Epclusa” www.fiercebiotech.com/biotech/atea...
Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial
Atea Pharmaceuticals’ hepatitis C prospect has
www.fiercebiotech.com
July 28, 2026 at 4:31 PM
“Atea ran the pivotal C-Beyond study to compare its once-daily fixed-dose combination of bemnifosbuvir & ruzasvir (BEM/RZR) to Gilead’s incumbent hepatitis C drug..a once-daily fixed-dose combination of sofosbuvir & velpatasvir, as Epclusa” www.fiercebiotech.com/biotech/atea...
Dexcom
Rybelsus
Sunosi
Prolia
Vraylar
Xofluza
Breztri
Lise
Kesimpta
Fasenra
Phexxi
Annovera
Austedo
Ingrezza
Veleesi
Mavyret
Imbruvica
Tepezza
Cabenuva
Krystexxa
Jublia
Austedo
Zeposia
Caplyta
Vuity
Opzelura
Epclusa
Vyvgart
Tezspire
Qelbree
Leqvio
Rybelsus
Sunosi
Prolia
Vraylar
Xofluza
Breztri
Lise
Kesimpta
Fasenra
Phexxi
Annovera
Austedo
Ingrezza
Veleesi
Mavyret
Imbruvica
Tepezza
Cabenuva
Krystexxa
Jublia
Austedo
Zeposia
Caplyta
Vuity
Opzelura
Epclusa
Vyvgart
Tezspire
Qelbree
Leqvio
January 31, 2025 at 1:53 PM
Dexcom
Rybelsus
Sunosi
Prolia
Vraylar
Xofluza
Breztri
Lise
Kesimpta
Fasenra
Phexxi
Annovera
Austedo
Ingrezza
Veleesi
Mavyret
Imbruvica
Tepezza
Cabenuva
Krystexxa
Jublia
Austedo
Zeposia
Caplyta
Vuity
Opzelura
Epclusa
Vyvgart
Tezspire
Qelbree
Leqvio
Rybelsus
Sunosi
Prolia
Vraylar
Xofluza
Breztri
Lise
Kesimpta
Fasenra
Phexxi
Annovera
Austedo
Ingrezza
Veleesi
Mavyret
Imbruvica
Tepezza
Cabenuva
Krystexxa
Jublia
Austedo
Zeposia
Caplyta
Vuity
Opzelura
Epclusa
Vyvgart
Tezspire
Qelbree
Leqvio
2/7 Je pravda, že devět farmakofirm uzavřelo dohody s Trumpem o snížení cen některých léků.
Gilead např. zlevnil lék proti hepatitidě C Epclusa o 90%, Amgen nabídl Aimovig se 60% a biosimilární Amjevita s 80% slevou.
Gilead např. zlevnil lék proti hepatitidě C Epclusa o 90%, Amgen nabídl Aimovig se 60% a biosimilární Amjevita s 80% slevou.
December 24, 2025 at 7:48 AM
2/7 Je pravda, že devět farmakofirm uzavřelo dohody s Trumpem o snížení cen některých léků.
Gilead např. zlevnil lék proti hepatitidě C Epclusa o 90%, Amgen nabídl Aimovig se 60% a biosimilární Amjevita s 80% slevou.
Gilead např. zlevnil lék proti hepatitidě C Epclusa o 90%, Amgen nabídl Aimovig se 60% a biosimilární Amjevita s 80% slevou.
Atea's hep C pill matches Gilead's in new data; AbCellera closes its second deal in two months.
endpoints.news/ateas-hep-c-...
endpoints.news/ateas-hep-c-...
Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two months
Atea's BEM/RZR matches Gilead's Epclusa in Phase 3; AbCellera partners with Vertex for $28M; LB Pharma raises $150M for schizophrenia drug.
endpoints.news
July 29, 2026 at 7:54 PM
Atea's hep C pill matches Gilead's in new data; AbCellera closes its second deal in two months.
endpoints.news/ateas-hep-c-...
endpoints.news/ateas-hep-c-...
Maybe consider reaching out to the patient support program? Many drugs, esp newer ones, have them. They can support access while patient gets insurance worked out. They may also be able to help with that too.
www.epclusa.com/saving-on-ep...
www.epclusa.com/saving-on-ep...
Save on the Cost of EPCLUSA (sofosbuvir 400mg/velpatasvir 100mg) | Patient Site
Discover how to save on the cost of ECPLUSA (sofosbuvir/velpatasvir). Learn about insurance coverage options and the co-pay coupon program for eligible patients. See Important Safety Information inclu...
www.epclusa.com
December 3, 2024 at 11:46 AM
Maybe consider reaching out to the patient support program? Many drugs, esp newer ones, have them. They can support access while patient gets insurance worked out. They may also be able to help with that too.
www.epclusa.com/saving-on-ep...
www.epclusa.com/saving-on-ep...
#AVIR Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-meets-both-its-primary-and-secondary-endpoints-h3rtcfpkuvuz.html
https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-meets-both-its-primary-and-secondary-endpoints-h3rtcfpkuvuz.html
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Atea Pharmaceuticals (Nasdaq: AVIR) reported positive topline Phase 3 C-BEYOND results in North America for its once-daily fixed-dose combination bemnifosbuvir/ruzasvir (BEM/RZR) in chronic hepatitis C virus (HCV). In the modified intent-to-treat population (n=905), BEM/RZR achieved a 93.9% sustained virologic response (SVR) at Week 24 versus 94.8% for standard-of-care sofosbuvir/velpatasvir (SOF/VEL; Epclusa), meeting the primary endpoint of statistical non-inferiority within a prespecified 5% margin.In patients without cirrhosis (n=721), 8 weeks of BEM/RZR achieved a 93.5% SVR versus 12 weeks of SOF/VEL with 94.6% SVR. In patients with cirrhosis (n=184), 12 weeks of each regimen yielded 95.4% SVR in both arms. Secondary endpoints, including per-protocol analysis, also met statistical non-inferiority. BEM/RZR was generally safe and well tolerated, with no drug-related serious adverse events or drug-related early discontinuations and safety comparable between arms. C-FORWARD, the companion Phase 3 trial outside North America with more than 880 patients enrolled, remains on track to report topline results in early 2027.
www.stocktitan.net
July 28, 2026 at 11:00 AM
#AVIR Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-meets-both-its-primary-and-secondary-endpoints-h3rtcfpkuvuz.html
https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-meets-both-its-primary-and-secondary-endpoints-h3rtcfpkuvuz.html
Treatments are now pan-genotypic, all oral regimens like Mayvret (8 weeks), or Epclusa (12 weeks).
October 30, 2025 at 8:58 PM
Treatments are now pan-genotypic, all oral regimens like Mayvret (8 weeks), or Epclusa (12 weeks).
Update on twitter ads:
Apparently algorithm has learned I’m
Not a hematologist but do treat Hep C & is trying mighty to sway me from a Mayvret preference back to an Epclusa preference
Apparently algorithm has learned I’m
Not a hematologist but do treat Hep C & is trying mighty to sway me from a Mayvret preference back to an Epclusa preference
November 24, 2024 at 10:53 AM
Update on twitter ads:
Apparently algorithm has learned I’m
Not a hematologist but do treat Hep C & is trying mighty to sway me from a Mayvret preference back to an Epclusa preference
Apparently algorithm has learned I’m
Not a hematologist but do treat Hep C & is trying mighty to sway me from a Mayvret preference back to an Epclusa preference
March 31, 2026 at 5:33 AM